Industry News (Joint Venture)

Hepatitis C Inhibitors to be Developed

Published in Hepatitis Weekly, December 15th, 1997

Bristol-Myers Squibb Co., Princeton, New Jersey, and Arris Pharmaceutical Corp., San Francisco, California, announced they have entered into an agreement to develop protease inhibitors to prevent the growth and spread of hepatitis C virus (HCV) infection.

Bristol-Myers Squibb receives exclusive development and marketing rights to any HCV protease inhibitors produced in the collaboration. In return, Bristol-Myers Squibb provides research funding as well as up-front, milestone, and royalty payments to Arris.

According to the terms of the agreement, Arris applies its proprietary Delta Technology to design potent and selective inhibitors of the protease...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (1997-12-15)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry